Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lestaurtinib
- Development stage
- Phase 3
- Lead developer
- Teva Pharmaceutical Industries
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lestaurtinib is an orally bioavailable indolocarbazole derivative and a small molecule multi-targeted tyrosine kinase inhibitor. It potently inhibits FMS-like tyrosine kinase 3 (FLT3), Janus kinase 2 (JAK2), and Tropomyosin receptor kinase A (TrkA), as well as Aurora kinase A and B. By inhibiting FLT3 autophosphorylation, it blocks FLT3 activity and induces apoptosis in tumor cells that overexpress FLT3. Lestaurtinib has been investigated primarily for the treatment of acute myelogenous leukemia (AML), especially in patients with FLT3 mutations, but has also undergone clinical trials for pancreatic cancer, prostate cancer, polycythemia vera (JAK2 V617F positive), essential thrombocytosis, and refractory neuroblastoma. The drug was originally developed from K252a as a semisynthetic staurosporine analog[1][4][5][6][8].
- Other names
- lestaurtinib111358-88-4
02
Targets
AURKA (Aurora kinase A)AURKB (Aurora kinase B)FLT3 (Fms related receptor tyrosine kinase 3)JAK2 (Janus kinase 2)NTRK1 (Tropomyosin-related receptor kinase A)NTRK2 (Tropomyosin-related kinase receptor type B)NTRK3 (Tropomyosin receptor kinase C)
Beyond the preview
Go deeper on lestaurtinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lestaurtinib.